Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05483465 · ClinicalTrials.gov registry record · Phase 4
The Effect of NAD Supplementation on Brain Vascular Health in Aging
A Phase 4 study of Aging, sponsored by University of Oklahoma.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 214
- Enrollment target
- 1
- Study location
NCT05483465: Recruiting Phase 4 study of Aging, sponsored by University of Oklahoma.
NCT05483465 is a Phase 4 study of Aging that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 214 participants, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05483465, a Phase 4 study of Aging, is actively recruiting participants, sponsored by University of Oklahoma.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 214 participants
- Enrollment target
- 1
- Study location
Study Summary
Daily consumption of one of the forms of Vitamin B3, the Nicotinamide Riboside (NR), energizes the body and combats cellular aging. This study is designed to test whether NR can also improve brain health and memory.
Primary Outcome
Functional near infrared spectroscopy (fNIRS) will be performed during the cognitive n-back task. fNIRS approach generates data that represent a relative change in oxygenated and deoxygenated hemoglobin measured over the cortical brain tissues. Neurovascular coupling will be evaluated as a change in oxy- and deoxy-hemoglobin between before and after treatment. Units of measure - beta. Reported as a %change from baseline, before and after treatment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Nicotinamide riboside
Study Locations (1)
Oklahoma
- University of Oklahoma Health Sciences Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2023-05-03 |
| Est. Completion | 2027-12 |
| Phase | Phase 4 |
What NCT05483465 shows while recruiting
NCT05483465 is an interventional study that assigns participants to a tested intervention. The registered 214 participants enrollment target is mid-sized for trials with a published cap, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Aging appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05483465 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT05483465 about?
NCT05483465 is a clinical study titled "The Effect of NAD Supplementation on Brain Vascular Health in Aging". Daily consumption of one of the forms of Vitamin B3, the Nicotinamide Riboside (NR), energizes the body and combats cellular aging. This study is designed to test whether NR can also improve brain health and memory.
What is the current status of trial NCT05483465?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 214 participants. The study started on 2023-05-03. Estimated completion is 2027-12.
What conditions does trial NCT05483465 study?
This clinical trial studies the following conditions: Aging.
What interventions are being tested in trial NCT05483465?
The interventions under investigation include: Placebo (DRUG), Nicotinamide riboside (DRUG).
Who is sponsoring clinical trial NCT05483465?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05483465 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05483465's enrollment target sits among peer trials
214 47th of 262 higher than 216 of 262 other Aging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses
RECRUITING · Phase 4
-
Cardiometabolic Consequences of the Loss of Ovarian Function
RECRUITING · Phase 4
-
A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults
RECRUITING · Phase 4
-
Role of Menopause in Thermoregulation
RECRUITING · Phase 4
-
Aging, Beta Blockers, and Thermoregulatory Responses
RECRUITING · Phase 4
-
Skin Barrier Function and Inflammation in Aging: The BIA Study
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04030507 · 214 participants · NA
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
- NCT04421248 · 214 participants · Phase 4
Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder
- NCT04667520 · 214 participants · NA
Testing a Lifestyle Physical Activity Intervention for Women With Depression in Alcohol Treatment
- NCT05418868 · 214 participants · Phase 1
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI